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Some cases of endometrial cancer are associated with a familial tumor and are referred to as hereditary nonpolyposis colorectal
cancer(HNPCCorLynchsyndrome).LynchsyndromeisthoughttobeinducedbygermlinemutationoftheDNAmismatchrepair
(MMR)gene.AnaberrationintheMMRgenepreventsaccuraterepairofbasemismatchesproducedduringDNAreplication.This
phenomenon can lead to an increased frequency of errors in target genes involved in carcinogenesis, resulting in cancerization of
the cell. On the other hand, aberrant DNA methylation is thought to play a key role in sporadic endometrial carcinogenesis.
Hypermethylation of unmethylated CpG islands in the promoter regions of cancer-related genes associated with DNA repair leads
to the cell becoming cancerous. Thus, both genetic and epigenetic changes are intricately involved in the process through which
cells become cancerous. In this review, we introduce the latest ﬁndings on the DNA mismatch repair pathway in endometrial
cancer.
1.Introduction
Theincidenceofendometrialcanceramongmalignantgyne-
cological tumors has increased with lifestyle and environ-
mental changes. In the US, 40,000 patients are diagnosed
with endometrial cancer annually, and 7,500 patients die of
this disease [1].
The number and prevalence of cases of endometrial
cancer have increased worldwide and control of this cancer is
urgently required. However, many aspects of the mechanism
of carcinogenesis and pattern of advancement are unclear.
Environmental factors such as obesity and a high estrogen
level are thought to play important carcinogenic roles, but
a close association with hereditary disposition has also been
suggested, since double cancer and an increased incidence of
cancer in relatives are common in patients with endometrial
cancer.
Lynch syndrome, also known as hereditary nonpolyposis
colorectal cancer (HNPCC), is a hereditary disease in which
thereisfrequentdevelopmentofcolorectal,endometrial,and
ovarian cancers. The cause is thought to be mutation of the
DNA mismatch repair (MMR) gene in germ cells. However,
the conventional explanation of the mechanism involv-
ing genetic changes—mutations of cancer-related genes—is
inadequate and epigenetic changes in endometrial cancer are
now being examined. In particular, aberrant DNA methyla-
tionis thoughttoplayakey roleinendometrial carcinogene-
sis. Breakdown of the DNA mismatch repair mechanism due
toDNAhypermethylationplaysaparticularlyimportantrole
in the development of endometrial cancer.
2. LynchSyndrome
Lynchsyndromeisahereditarydiseasethatincludesfrequent
developmentofcolorectal,endometrial,andovariancancers,
and which is inherited in an autosomal dominant manner.
Lynch syndrome is caused by a hereditary defect in the
DNA mismatch repair (MMR) gene and the incidences in
colorectal and endometrial cancers are 2-3% and 1-2%,
respectively [2]. This syndrome was initially reported by2 Molecular Biology International
Table 1: Clinical diagnostic criteria for HNPCC.
Amsterdam minimum criteria (1990)
(1) At least 3 cases of colorectal cancer in relatives (veriﬁed path-
ologically)
(2) One is a ﬁrst degree relative of the other two
(3) At least two successive generations should be aﬀected
(4) One case of colorectal cancer diagnosed before the age of 50
years old
(5) FAP should be excluded
Revised amsterdam criteria II (1998)
(1) At least 3 relatives with an HNPCC-associated cancer (cancer
of the colorectum, endometrium, small bowel, ureter or renal
pelvis)
(2–5) As for the minimum criteria
Wartin et al. in 1913 in a family with a high risk of devel-
opment of colorectal cancer. Subsequent analysis of this
family led Lynch to propose the disease concept of cancer
family syndrome in 1971 [3, 4].
Six variants of the MMR gene, the causative gene
in Lynch syndrome, have been cloned: hMSH2, hMLH1,
hMSH3, hMSH6, hPMS1, and hPMS2.A na b e r r a t i o ni no n e
of these genes prevents accurate repair of base mismatches
produced during DNA replication. In Lynch syndrome with
anhMLH1or hMSH2mutation,thefrequenciesofcolorectal
and endometrial cancers are 68% and 62%, respectively, and
the lifetime risk of developing endometrial cancer is higher
than that for colorectal cancer in women [5].
DiagnosisofLynchsyndromeisbasedonclinicalcriteria.
In 1990, the International Collaborative Group- (ICG-)
HNPCC established the following diagnostic criteria for
HNPCC, which are referred to as the classical Amsterdam
criteria: (1) HNPCC is diagnosed when 3 or more patients
with histologically conﬁrmed colorectal cancer are present in
a family line and one is a ﬁrst relative of the other two; (2)
colorectal cancer develops over two generations; (3) one case
is diagnosed at younger than 50 years old [6]. In 1999, the
new Amsterdam Criteria (Amsterdam II) [7]( Table 1)w e r e
published. These criteria address endometrial cancer, small
intestinal cancer, urethral cancer, and kidney cancer, in addi-
tion to the colorectal cancer included in the classic criteria.
3. DNA Mismatch RepairGeneand
EndometrialCancer
DNA mismatch repair (MMR) system corrects DNA base
pairing errors in newly replicated DNA. Mispaired nucleot-
ides may be present after DNA replication, along with small
insertion/deletion mutations that tend to occur at repetitive
sequences. The MMR system is an excision/resynthesis sys-
tem that can be divided into 4 phases: (i) recognition of a
mismatch, (ii) recruitment of repair enzymes, (iii) excision
of the incorrect sequence, and (iv) resynthesis by DNA
polymerase using the parental strand as a template. This sys-
tem is conserved through evolution from bacteria to human
[8].
An aberration in one of MMR genes prevents accurate
repairofbasemismatchesproducedduringDNAreplication,
resulting in production of a DNA chain of altered length,
particularly in highly repeated sequences (microsatellites).
This phenomenon is called microsatellite instability (MSI)
and can lead to an increased frequency of errors in target
genes involved in carcinogenesis, resulting in cancerization
of the cell. Among the MMR genes, germline mutations of
hMLH1onchromosome3andhMSH2onchromosome2are
thought to cause most cases of HNPCC. Mutation of hMSH6
has also been proposed to be important for development of
HNPCC-associated endometrial cancer, but the details are
unclear (Figure 1)[ 9].
4. ClinicalDiagnosticCriteriafor
Lynch Syndrome
Since the Amsterdam Criteria for Lynch syndrome were pro-
posed in 1991, several other diagnostic criteria, including the
Japanese Criteria and the Bethesda Criteria, have been pub-
lished. The confusion caused by the diﬀerent criteria was
resolved by revision of the Amsterdam Criteria by the
ICG-HNPCC in 1999, to give the new Amsterdam Criteria
[7]( Table 1). These criteria address endometrial cancer,
small intestinal cancer, urethral cancer, kidney cancer, and
colorectal cancer. Cases not meeting the classical Amsterdam
Criteria may meet the new Amsterdam Criteria, and this
has resulted in an increased number of cases diagnosed as
Lynch syndrome. In addition, discovery of Lynch syndrome
is now possible through investigation of familial histories of
endometrialcancerpatients.Therevisionalsorecognizedthe
importance of cooperation among gynecologists for identif-
ication of Lynch syndrome. However, one concern with the
new criteria is the omission of ovarian, breast, and stomach
cancer, which may also be associated with Lynch syndrome.
The 1999 revised Amsterdam criteria II include endome-
trial cancer as a Lynch syndrome-related tumor, but women
who develop endometrial cancer as the initial cancer and pa-
tients with a family tree with insuﬃcient details are not
included; thus, a high false negative rate has been reported
based on these criteria [5]. For colorectal cancer, the
Bethesda criteria require MSI testing, but this is not appli-
cable for patients who develop endometrial cancer as the ini-
tial cancer. Thus, there is a need to establish criteria for selec-
tion of patients with endometrial cancer who should under-
go screening [10].
5 .Car c ino m ao fth eLo w e rU t e rineSegm e nt
andLynchSyndrome
Endometrial cancer arises from the uterine body and fundus
in many cases, but can also originate from the lower region
of the uterine body through the upper region of the cervix.
Suchtumorsarereferredtoascarcinomaoftheloweruterine
segment (LUS) or isthmus and account for 3–6.3% of all
cases of endometrial cancer. The association of carcinoma of
the LUS with Lynch syndrome has attracted recent attention.
The frequency of Lynch syndrome in general endometrial
cancer is 1-2% [2]. In contrast, Lynch syndrome has a highMolecular Biology International 3
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frequency in cases of carcinoma of the LUS, with one report
in the US suggesting that 29% of such cases could also
be diagnosed with Lynch syndrome and that the hMSH2
mutation was present at a high frequency in these cases [11].
Demonstration of an association between carcinoma of the
LUS and Lynch syndrome in a large-scale survey would allow
patients with carcinoma of the LUS to be classiﬁed as a high-
risk group for Lynch syndrome [12].
6.MicrosatelliteInstabilityand
EndometrialCancer
Microsatellite instability occurs when the mismatch repair
system is damaged. Microsatellites are DNA sequences of
repeating units of 1 to 5 base pairs. Abnormalities in the mis-
match repair system may cause replication errors in the re-
peating unit, leading to changes in length that are referred to
as MSI. MSI caused by MMR gene aberration is detectable
by PCR using microsatellite markers. In screening for Lynch
syndrome, use of 5 microsatellite markers, two mononu-
cleotide repeats (BAT26 and BAT25) and three dinucleotide
repeats (D5S346, D2S123, and D17S250), is recommended
[13]. MSI is observed in certain types of cancer, including
20 to 30% of cases of endometrial cancer [14]. These results
suggest that MMR gene abnormalities occur frequently in
endometrial cancer.
To investigate the status and characteristics of familial
endometrial cancer, Banno et al. [15] surveyed the familial
and medical histories of 385 patients who underwent treat-
ment for endometrial cancer. MSI analysis was performed
in 38 of these patients. The familial histories showed that
2 of the 385 cases met the new Amsterdam Criteria for
Lynch syndrome, giving a rate of Lynch syndrome of about
0.5%. Investigation of familial accumulation of cancer in 890
relatives (439 men and 451 women) of the 38 endometrial
cancer patients who underwent MSI analysis revealed high
incidences of endometrial cancer, colorectal cancer, and
ovarian cancer, suggesting that a hereditary factor common
to Lynch syndrome is also involved in endometrial cancer.
MSI analysis detected at least one of 5 microsatellite markers
(D2S123, D3S1284, D5S404, D9S162, and hMSH2 intron
12) in 12 of the 38 cases (31.6%). This rate is very high
compared to MSI in cancers of other organs, demonstrating
that abnormal DNA mismatch repair plays an important
role in endometrial cancer. The patients with MSI showed
a tendency to have double cancer (such as ovarian cancer)
compared with patients with microsatellite stability (MSS),
although the diﬀerence was not signiﬁcant (27% versus
15%). Regarding prognosis, none of the MSI-positive cases
were fatal (0/11, 0%), while 5 MSI-negative (MSS) cases
were fatal (5/27, 19%). The diﬀerence was not signiﬁcant,
but this tendency is similar to that for Lynch syndrome-as-
sociated colorectal cancer. The incidences of moderately dif-
ferentiated adenocarcinoma G2 (36%) and poorly diﬀer-
entiated adenocarcinoma G3 (18%) tended to be higher
in MSI-positive endometrial cancer, although again the
diﬀerence was not signiﬁcant. These ﬁndings appear contra-
dictory with the favorable prognosis, but interestingly they
may reﬂect the biological characteristics of endometrial can-
cer induced by abnormal DNA mismatch repair [16].
7. Screeningfor Endometrial Cancer
and Prophylactic Hysterectomyin
Lynch Syndrome
Women with Lynch syndrome have a high risk for endome-
trial cancer, with a life-long incidence of 40% to 60%, which
is similar to or greater than that of colon cancer [17].
Therefore, a woman diagnosed with Lynch syndrome should
undergo screening or prophylactic hysterectomy.
Potential screening methods include transvaginal ultra-
sound and endometrial biopsy. Transvaginal or transabdom-
inal sonography is used to evaluate endometrial conditions
and thickness. Some studies have shown a high false-positive4 Molecular Biology International
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rate and poor eﬃcacy [18, 19], while others have shown high
sensitivity and negative predictive values [20]. Endometrial
biopsy is not used for general screening but may be useful for
patients with Lynch syndrome with a high risk for endome-
t r i a lc a n c e r .T h u s ,w o m e nw h oh a v eaD N Am i s m a t c hr e p a i r
gene mutation or a family history of this mutation should
undergo a biopsy every year at the age of 30–35 [21].
One article has reviewed 5 papers reporting results of
gynecological cancer surveillance in Lynch syndrome. Of the
ﬁve articles included in this review, three were retrospective
observational study. One study was prospective cohort stud-
y in Finland. Another study was a prospective clinical study,
which evaluated the performance of hysteroscopy and endo-
metrial biopsy in women at risk of Lynch syndrome in
France.Thisarticleconcludedthat,althoughsurveillancecan
detect premalignant lesions, it does not completely remove
the risk of invasive cancer and it remains unclear whether
surveillance for gynecological cancer in women with Lynch
syndrome would signiﬁcantly decrease mortality [22].
Prophylactic hysterectomy has not been thought to
reduce the cancer risk in women with Lynch syndrome. In
1997, the Cancer Genetics Studies Consortium suggested
thattherewasinsuﬃcientevidencetorecommendthatwom-
en with Lynch syndrome should have prophylactic surgery
to reduce the risk of gynecologic cancer [23]. However, pro-
phylactic hysterectomy has been realistically conducted in
some institutions. The eﬀects of prophylactic hysterectomy
are of interest. Schmeler et al. [24] showed that prophylactic
hysterectomy had a cancer-protective eﬀect based on a
retrospective cohort analysis in 315 women with a detected
hMLH1, hMSH2, or hMSH6 germline mutation from 1973
to 2004. Outcomes were compared between 61 patients
who underwent hysterectomy for prophylaxis or benign dis-
ease and 210 patients who did not undergo prophylactic hy-
sterectomy. None of the 61 patients in the hysterectomy
group developed endometrial cancer, whereas 69 (33%) in
the nonhysterectomy group had endometrial cancer. These
results indicate that prophylactic hysterectomy signiﬁcantly
decreased the development of endometrial cancer.
These results suggest that further studies should be
conducted to compare the morbidity and mortality between
screening using sonography or endometrial biopsy and pro-
phylactic surgery.
8. DNA Hypermethylationand
EndometrialCancer
Epigenetics refers to the information stored after somatic cell
division that is not contained within the DNA base sequence.
Recent ﬁndings have shown that epigenetic changes—
selective abnormalities in gene function that are not due to
DNA base sequence abnormalities—play a signiﬁcant role
in carcinogenesis in various organs. In particular, the rela-
tionship between cancer and aberrant hypermethylation of
speciﬁcgenomeregionshasattractedattention.Acompletely
new model for the mechanism of carcinogenesis has been
proposed in which hypermethylation of unmethylated CpG
islands in the promoter regions of cancer-related genes in
normal cells silences these genes and leads to the cell becom-
ing cancerous (Figure 2).
The main diﬀerence between epigenetic abnormalities
and genetic abnormalities such as gene mutations is that epi-
genetic changes are reversible and do not involve changes
in base sequence. This suggests that restoration of gene ex-
pression is possible and that epigenetic data may lead to im-
portant molecular targets for treatment. Attempts have be-
gun to detect aberrant DNA methylation of cancer cells pre-
sent in minute quantities in biological samples and to ap-
ply the results to cancer diagnosis, prediction of the risk
of carcinogenesis, and deﬁnition of the properties of aMolecular Biology International 5
particular cancer. The MMR gene hMLH1 is a typical gene
that is silenced by DNA methylation. In endometrial cancer,
hMLH1silencingisfoundinapproximately40%ofcasesand
is an important step in the early stages of carcinogenesis,
with the loss of DNA mismatch repair function proposed
to lead to mutation of genes such as PTEN. In patients
with endometrial cancer, Banno et al. found aberrant hyper-
methylation of hMLH1, APC, E-cadherin, and CHFR in
40.4%, 22.0%, 14.0%, and 13.3% of cases, respectively. A sig-
niﬁcant decrease in protein expression was found in patients
with aberrant methylation of hMLH1 (P<0.01) and E-cad-
herin (P<0.05), and aberrant methylation of hMLH1 was
also found in 14.3% of patients with atypical endometrial
hyperplasia (AEH). However, no aberrant methylation of the
four cancer-related genes was found in patients with a nor-
malendometrium.Theseresultsindicatethataberrantmeth-
ylation of speciﬁc genes associated with carcinogenesis in
e n d o m e t r i a lc a n c e rd o e sn o to c c u ri nan o r m a le n d o -
metrium. Aberrant methylation of hMLH1 was most fre-
quent, and the observation of this phenomenon in AEH,
which is found in the ﬁrst stage of endometrial cancer, sup-
ports the hypothesis that aberrant methylation of hMLH1 is
an important event in carcinogenesis in endometrial cancer
[10, 25].
9. Conclusion
The DNA mismatch repair pathway is important in carcino-
genesis of endometrial cancer. Recent analyses have shown
that the MMR pathway can be impaired via both genetic
and epigenetic mechanisms. Genetically, Lynch syndrome in
cases of endometrial cancer is caused by a hereditary defect
in the MMR gene. However, there have been fewer studies on
endometrialcancercomparedtocolorectalcancerinpatients
with Lynch syndrome. Clariﬁcation of the pathology and
development of screening and genetic tests are required for
further progress in this area. Epigenetic research in endome-
trial cancer suggests that damage to the mismatch repair sys-
tem plays a signiﬁcant role in carcinogenesis and that DNA
hypermethylation is important in this mechanism. Many
attempts are currently being made to use epigenetic abnor-
malities as new methods of diagnosis and treatment based
on control of methylation. Further studies of the genetic and
epigeneticmechanismsmayhavepotentialfordiagnosis,risk
assessment, and treatment of endometrial cancer.
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